teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 11 Projects Releases Packages Wiki Activity Actions 48

extract: 2025-05-01-nejm-semaglutide-mash-phase3-liver

Browse source 
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents 2026-03-16 11:33:17 +00:00
parent 8e31531059
commit acfb15af90
3 changed files with 25 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

6
domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
View file

@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti
MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
### Additional Evidence (extend)
*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-16*
MASH is projected to become the leading cause of liver transplantation. If GLP-1s can resolve steatohepatitis at 62.9% rate and slow fibrosis progression, this prevents late-stage liver disease requiring transplantation. However, the Value in Health Medicare study showed only $28M MASH savings — surprisingly small given clinical magnitude, likely because MASH progression to transplant takes decades. This suggests the economic benefit window extends far beyond typical budget scoring horizons, reinforcing the chronic-use inflationary thesis through 2035.
---
Relevant Notes:

6
domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md
View file

@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
- Nature Medicine: additive benefits with SGLT2 inhibitors
- First GLP-1 to receive FDA indication for CKD in T2D patients
### Additional Evidence (extend)
*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-16*
Phase 3 trial shows semaglutide 2.4mg achieves 62.9% resolution of steatohepatitis without worsening fibrosis vs 34.3% placebo. Meta-analysis confirms GLP-1 RAs significantly improve histologic MASH resolution, decrease liver fat deposition, improve hepatocellular ballooning, and reduce lobular inflammation. Some hepatoprotective benefits appear at least partly independent of weight loss, suggesting direct liver effects beyond metabolic improvement. Combined with established CV and kidney protection, this adds a third major organ system to the multi-organ protection profile.
---
Relevant Notes:

14
inbox/archive/2025-05-01-nejm-semaglutide-mash-phase3-liver.md
View file

@ -7,9 +7,13 @@ date: 2025-05-01
domain: health
secondary_domains: []
format: paper
status: unprocessed
status: enrichment
priority: medium
tags: [glp-1, semaglutide, MASH, NASH, liver-disease, organ-protection]
processed_by: vida
processed_date: 2026-03-16
enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
extraction_model: "anthropic/claude-sonnet-4.5"
---
## Content
@ -39,3 +43,11 @@ Phase 3 trial of semaglutide 2.4mg in patients with MASH and moderate or advance
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
WHY ARCHIVED: Third organ-protection pathway (after CV and kidney) strengthens the case that GLP-1s should be evaluated as multi-organ protective agents, not just weight loss drugs
EXTRACTION HINT: The multi-organ protection thesis may justify reframing the existing GLP-1 claim from a weight-loss-economics frame to a metabolic-disease-prevention frame
## Key Facts
- Semaglutide 2.4mg achieved 62.9% resolution of steatohepatitis without worsening fibrosis vs 34.3% placebo in Phase 3 trial
- Meta-analysis shows GLP-1 RAs reduce risk of major CV events, clinically significant portal hypertension, and all-cause mortality in MASLD/MASH patients
- Resmetirom (Rezdiffra) was approved for MASH in March 2024 as dedicated MASH therapy
- MASH is projected to become leading cause of liver transplantation
- Value in Health Medicare study estimated only $28M MASH savings from GLP-1s